Notable News

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology. Meagan Parrish, Lead Editor PharmaVoice Published May 2, 2022 – Many pharma execs find that a personal experience with a patient serves as a catalyst to enter the field. For Dr. Thomas Bock, CEO of […]

Industry Dealmaker Joins Notable to Accelerate In-licensing Strategy to Fuel Predictive Precision Platform and Pipeline Foster City, Calif., January 6, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, announced the appointment of Kevin Lynch, Ph.D., M.B.A, as Chief Business Officer. Dr. Lynch has decades of deal-making experience within pharma, and recently led […]

Studies demonstrate high correlation between predicted response by Notable’s predictive precision medicines platform and actual clinical response, short-term and at one year Interim analyses of studies with MD Anderson Cancer Center and Texas Children’s Hospital investigators corroborate platform prediction data from Standford University collaboration Foster City, Calif., December 16, 2021 – Notable Labs, Inc. (Notable), […]

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform With The Goal Of Assessing Patient Responsiveness To Fosciclopirox Foster City, Calif. and Kansas City, Mo., December 1, 2021 – Notable Labs, Inc. (Notable), a clinical-stage predictive precision therapeutics company and CicloMed LLC (CicloMed), a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of […]

Foster City, Calif., November 23, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, today announced the appointment of Chris Whitmore as Chief Financial Officer. In this role, Mr. Whitmore will be a key member of the executive leadership team and will lead Notable’s financial strategy, planning […]

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platformto Accelerate Clinical Development and Maximize Patient Outcomes Foster City, Calif., November 22, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, today announced two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. “These two clinical […]

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform to Accelerate Clinical Trial Timelines and Maximize Patient Outcomes Volasertib is a PLK-1 inhibitor with therapeutic potential across a range of tumor types Foster City, Calif., November 11, 2021 – Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights […]

FOSTER CITY, CA – June 10, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced that it will be attending BIO Digital 2021, a key international biotech partnering event held virtually on June 14-18. During the conference Notable […]

FOSTER CITY, CA – June 4, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced top-line results from its clinical response prediction technology platform in a pediatric acute myeloid leukemia (AML) study to be presented at the 2021 […]

FOSTER CITY, CA – March 31, 2021 – Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced the appointment of Thomas A. Bock, MD, MBA, as Chief Executive Officer.